NCT02642939 - Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 15, 2020

Study Completion Date

October 15, 2020

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Mifepristone

Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.

Trial Locations (1)

19027

Cooper Institute for Reproductive Hormonal Disorders, Melrose Park